Compare IRTC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRTC | LQDA |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.8B |
| IPO Year | 2016 | 2020 |
| Metric | IRTC | LQDA |
|---|---|---|
| Price | $121.92 | $43.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 8 |
| Target Price | ★ $171.33 | $54.38 |
| AVG Volume (30 Days) | 416.0K | ★ 5.2M |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.71 | 51.81 |
| EPS | N/A | ★ 1.26 |
| Revenue | ★ $747,138,000.00 | $158,320,000.00 |
| Revenue This Year | $19.35 | $357.27 |
| Revenue Next Year | $16.58 | $1.34 |
| P/E Ratio | ★ N/A | $33.88 |
| Revenue Growth | 26.24 | ★ 1031.18 |
| 52 Week Low | $100.70 | $22.05 |
| 52 Week High | $210.01 | $93.61 |
| Indicator | IRTC | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 66.89 | 50.31 |
| Support Level | $113.82 | $35.00 |
| Resistance Level | $125.38 | $46.67 |
| Average True Range (ATR) | 3.99 | 2.98 |
| MACD | 1.98 | 2.63 |
| Stochastic Oscillator | 95.44 | 93.07 |
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.